We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

New Anti-CARMA Antibody Series Released by AnaSpec

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

AnaSpec has introduced a new series of IHC validated antibodies, Anti-CARMA/CARD/Bimp antibodies.

CARMA proteins are scaffold molecules that belong to the membrane-associated guanylate kinase-like (MAGUK) and the caspase-associated recruitment domain (CARD) protein families. They play critical role in antigen receptor signaling pathways.1-4 CARMA-1 (CARD-11) CARMA-2 (CARD-14), and CARMA-3 (CARD-10) share homologous sequence and functions but are found in different tissues.

CARMA1 is predominantly located in lymphoid tissue. CARMA-1 protein associates with lipid rafts1 and interacts with Bcl10, that is required for activation of TCR induced NFkB signaling pathway. Specifically, CARMA-1 N-terminal CARD domain binds to Bcl10 CARD motif. It is also essential for protein-induced IL-2 and INF-? production. CARMA-2 is mostly found in placenta. CARMA-2 protein induces NF?B activation; however, its signaling pathway it is not yet known.

CARMA-3 is most abundant in nonhematopoietic cells.5 CARMA-3 protein physically associates with IKK complex and induces NF?B activation via LPA signaling pathway. CARMA genes deactivation studies in mice resulted in reduced immunoglobulin levels and absence of TCR-induced NF?B activation. This suggests that CARMA mutations may lead to adaptive and innate immunity malfunction.

Immunohistochemistry of these antibodies was performed by an anatomic pathologist on formalin-fixed, paraffin-embedded human or mouse tissues. Table 1 summarizes the IHC results. At least 22 different human or mouse tissues or cell types, including positive and negative tissues were used for each antibody tested. Dilutions of the antibodies at 2.5, 5, 10 and 20 ug/ml were tested, with the optimal concentration found to be at 10 ug/ml. These antibodies, provided at 50 ug, are sufficient for at least 5 IHCs.

Moderate to strong staining with minimal background staining at the expected target tissues were observed for the antibodies. A representative image from a positively stained tissue is shown for each antibody. It shows the localization of the antibody as the precipitated red signal, with a hematoxylin purple nuclear counterstain.

Anti-CARMA Antibodies:

Anti-CARMA-1/CARD-11, human, Cat# 54982

Anti-CARMA-1/CARD-11, mouse, Cat# 54985

Anti-CARMA-2/CARD-14,human, Cat# 54983

Anti-CARMA-3/CARD-10,human, Cat# 54984

Anti-CARMA-3/CARD-10, mouse, Cat# 54987.